Human CD8 alpha&beta (CD8A&CD8B) Heterodimer Protein

$410.00 100ug

$3330.00 1000ug

Min. Order100ug
Purity＞90%
Cas No
Supply AbilitySubject to availability
Update time2026-03-27

ACROBiosystems

VIP1Y

China

Since:2010-07-22

Address:4th Floor, Building 4, No. 8 Hongda North Road, Beijing Economic-Technological Development Area (BDA

show less show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Manufacturer

Chemical Properties

Product Name	Human CD8 alpha&beta (CD8A&CD8B) Heterodimer Protein
CAS No
EC-No
Min. Order	100ug
Purity	＞90%
Supply Ability	Subject to availability
Release date	2026/03/27

Synonym
CD8 alpha & beta, CD8A & CD8B
Source
Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free (CDA-H52W5) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 & Leu 22 - Pro 170 (Accession # P01732 & P10966-1).
Predicted N-terminus: Ser 22 & Leu 22
Request for sequence
Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version
The protein has a calculated MW of 19.5 kDa & 22.1 kDa. The protein migrates as 28-30 kDa and 31-33 kDa under reducing (R) condition, and 30-32 kDa and 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

show less show more

Company Profile Introduction

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.